Overview

A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subjects With Advanced Pancreatic Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-30
Target enrollment:
Participant gender:
Summary
To evaluate the preliminary safety and tolerability of iNKT cell injection after infusion in each group of subjects, and to determine the maximum tolerated dose (MTD) and/or the recommended dose for extended studies.
Phase:
NA
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine